FDA Pharmacoepidemiology Office Adds Jonca Bull
This article was originally published in The Pink Sheet Daily
Executive Summary
ODE V director joins effective May 2 as deputy director, leaving only one major vacancy in OPaSS. Reorganization of the Office of New Drugs is eliminating ODE V.